{"filing":{"accession_number":"0001628280-26-051900","cik":"0001723128","ticker":"AMRX","company_name":"Amneal Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"amrx-20260803.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026051900/amrx-20260803.htm"},"events":[{"id":23135,"run_id":20934,"accession_number":"0001628280-26-051900","anchor_item_number":"1.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"Amneal Pharmaceuticals entered into Amendment No. 3 to its Term Loan Credit Agreement on August 3, 2026, involving a repricing and restructuring of approximately $2.084 billion in term loans ($2.039 billion converted plus $45.2 million new), with an estimated annual interest expense reduction of approximately $12 million.","company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23285,"accession_number":"0001628280-26-051900","item_number":"1.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Amneal entered into Amendment No. 3 to its Term Loan Credit Agreement on August 3, 2026, which involved a repricing and restructuring of approximately $2.084 billion in term loans ($2.039 billion converted plus $45.2 million new). Although technically an amendment to existing debt rather than a new issuance, the creation of new term loans with modified terms and the material reduction in interest expense (~$12 million annually) constitute a significant modification of the company's direct financial obligations. This falls under debt_issuance as the most appropriate category for material changes to debt structure and terms.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:36:10.177617+00:00","company_name":"","ticker":null,"filing_date":""},{"id":23286,"accession_number":"0001628280-26-051900","item_number":"2.03","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 2.03 discloses the creation of a direct financial obligation through \"Amendment No. 3 to Term Loan Credit Agreement\" dated August 3, 2026, involving Amneal Pharmaceuticals LLC, lenders, and JPMorgan Chase Bank as administrative agent. The filing references Item 1.01 (which typically covers material agreements and debt arrangements) and mentions \"estimated savings related to the entry into the Repricing Amendment,\" indicating a material modification to existing debt terms. This amendment to a term loan credit facility constitutes a material debt-related obligation disclosure under Item 2.03.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:36:10.177617+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23285,"accession_number":"0001628280-26-051900","item_number":"1.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Amneal entered into Amendment No. 3 to its Term Loan Credit Agreement on August 3, 2026, which involved a repricing and restructuring of approximately $2.084 billion in term loans ($2.039 billion converted plus $45.2 million new). Although technically an amendment to existing debt rather than a new issuance, the creation of new term loans with modified terms and the material reduction in interest expense (~$12 million annually) constitute a significant modification of the company's direct financial obligations. This falls under debt_issuance as the most appropriate category for material changes to debt structure and terms.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:36:10.177617+00:00","company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","filing_date":"2026-08-03"},{"id":23286,"accession_number":"0001628280-26-051900","item_number":"2.03","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 2.03 discloses the creation of a direct financial obligation through \"Amendment No. 3 to Term Loan Credit Agreement\" dated August 3, 2026, involving Amneal Pharmaceuticals LLC, lenders, and JPMorgan Chase Bank as administrative agent. The filing references Item 1.01 (which typically covers material agreements and debt arrangements) and mentions \"estimated savings related to the entry into the Repricing Amendment,\" indicating a material modification to existing debt terms. This amendment to a term loan credit facility constitutes a material debt-related obligation disclosure under Item 2.03.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:36:10.177617+00:00","company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","filing_date":"2026-08-03"}]}